LivaNova (NASDAQ:LIVN) Raised to Strong-Buy at Zacks Research

LivaNova (NASDAQ:LIVN) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

LIVN has been the topic of several other research reports. Mizuho increased their price target on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Barclays upped their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. KeyCorp boosted their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Robert W. Baird cut their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.38.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $78.27 on Tuesday. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $85.27. The business has a 50-day moving average of $78.00 and a two-hundred day moving average of $69.36. The stock has a market capitalization of $4.30 billion, a P/E ratio of 40.14 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the prior year, the company posted $0.88 EPS. The firm’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts predict that LivaNova will post 3.73 EPS for the current fiscal year.

Insider Activity

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of LivaNova by 18.2% during the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock worth $151,000 after purchasing an additional 283 shares during the period. Pacer Advisors Inc. lifted its stake in shares of LivaNova by 4.1% in the first quarter. Pacer Advisors Inc. now owns 17,336 shares of the company’s stock valued at $1,102,000 after buying an additional 675 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of LivaNova in the first quarter valued at about $665,000. Janus Henderson Group PLC grew its position in LivaNova by 1,978.8% during the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after buying an additional 448,703 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in LivaNova by 103.6% during the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock worth $103,000 after buying an additional 826 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.